Free Trial

GENFIT (GNFT) Competitors

GENFIT logo
$3.93 +0.05 (+1.29%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GNFT vs. QURE, SANA, AKBA, PHAT, AMLX, AVXL, TSHA, AVBP, NAGE, and GYRE

Should you be buying GENFIT stock or one of its competitors? The main competitors of GENFIT include uniQure (QURE), Sana Biotechnology (SANA), Akebia Therapeutics (AKBA), Phathom Pharmaceuticals (PHAT), Amylyx Pharmaceuticals (AMLX), Anavex Life Sciences (AVXL), Taysha Gene Therapies (TSHA), ArriVent BioPharma (AVBP), Niagen Bioscience (NAGE), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.

GENFIT vs. Its Competitors

uniQure (NASDAQ:QURE) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

In the previous week, uniQure had 3 more articles in the media than GENFIT. MarketBeat recorded 3 mentions for uniQure and 0 mentions for GENFIT. uniQure's average media sentiment score of 0.00 equaled GENFIT'saverage media sentiment score.

Company Overall Sentiment
uniQure Neutral
GENFIT Neutral

uniQure has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, GENFIT has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.

GENFIT has higher revenue and earnings than uniQure.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$27.12M36.09-$239.56M-$3.92-4.55
GENFIT$76.77M2.56$1.63MN/AN/A

78.8% of uniQure shares are owned by institutional investors. Comparatively, 2.2% of GENFIT shares are owned by institutional investors. 4.8% of uniQure shares are owned by company insiders. Comparatively, 4.2% of GENFIT shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

uniQure presently has a consensus price target of $37.45, indicating a potential upside of 109.95%. GENFIT has a consensus price target of $9.00, indicating a potential upside of 129.01%. Given GENFIT's higher probable upside, analysts clearly believe GENFIT is more favorable than uniQure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
uniQure
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.00
GENFIT
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

GENFIT has a net margin of 0.00% compared to uniQure's net margin of -1,387.98%. GENFIT's return on equity of 0.00% beat uniQure's return on equity.

Company Net Margins Return on Equity Return on Assets
uniQure-1,387.98% -1,010.74% -33.27%
GENFIT N/A N/A N/A

Summary

GENFIT beats uniQure on 7 of the 13 factors compared between the two stocks.

Get GENFIT News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNFT vs. The Competition

MetricGENFITMED IndustryMedical SectorNASDAQ Exchange
Market Cap$196.50M$3.16B$5.78B$9.92B
Dividend YieldN/A2.28%6.67%4.51%
P/E RatioN/A21.2975.8626.67
Price / Sales2.56472.84556.21121.26
Price / Cash56.4745.1137.1158.92
Price / Book2.629.9011.436.07
Net Income$1.63M-$53.47M$3.29B$266.42M
7 Day Performance1.00%2.36%0.61%0.04%
1 Month Performance4.52%8.17%6.90%3.92%
1 Year Performance-6.21%13.33%59.44%23.82%

GENFIT Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNFT
GENFIT
1.6855 of 5 stars
$3.93
+1.3%
$9.00
+129.0%
-8.8%$196.50M$76.77M0.00120Gap Up
QURE
uniQure
1.9246 of 5 stars
$15.55
-1.0%
$37.45
+140.9%
+227.7%$861.41M$27.12M-3.97500News Coverage
Analyst Forecast
SANA
Sana Biotechnology
2.6994 of 5 stars
$3.35
-6.4%
$8.00
+138.8%
-45.8%$851.35MN/A-3.16380News Coverage
Positive News
AKBA
Akebia Therapeutics
3.821 of 5 stars
$3.03
-5.0%
$6.75
+122.8%
+116.5%$845.81M$160.18M-17.82430
PHAT
Phathom Pharmaceuticals
3.0909 of 5 stars
$11.57
-2.9%
$17.50
+51.3%
-29.4%$844.94M$114.04M-2.45110
AMLX
Amylyx Pharmaceuticals
2.5997 of 5 stars
$8.50
-8.6%
$11.75
+38.2%
+376.1%$829.26M$87.37M-3.40200News Coverage
Positive News
AVXL
Anavex Life Sciences
3.9656 of 5 stars
$9.40
-1.4%
$44.00
+368.1%
+66.5%$818.57MN/A-16.4940Positive News
TSHA
Taysha Gene Therapies
2.0137 of 5 stars
$2.92
-2.7%
$8.29
+183.8%
+57.5%$818.39M$8.10M-8.59180News Coverage
Positive News
AVBP
ArriVent BioPharma
2.517 of 5 stars
$19.35
-3.8%
$39.14
+102.3%
-25.3%$815.84MN/A-4.8140Positive News
NAGE
Niagen Bioscience
2.3053 of 5 stars
$10.03
+0.5%
$13.42
+33.8%
N/A$795.93M$99.60M47.76120
GYRE
Gyre Therapeutics
1.5677 of 5 stars
$8.20
+0.2%
N/A-38.7%$787.84M$105.76M820.8240High Trading Volume

Related Companies and Tools


This page (NASDAQ:GNFT) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners